Ahren is a deep tech and deep science investment firm established by Alice Newcombe-Ellis and science partners to provide long term capital. The firm maintains offices in Cambridge, London, and Boston with a portfolio that includes Graphcore and ZOE.
Portfolio
4
companies
AUM
£550M
under management
Bitfount
Federated AI platform enabling secure clinical research collaboration without data sharing.
Constructive Bio
Constructive Bio rewrites genomes to turn living cells into sustainable biofactories.
Nu Quantum
Nu Quantum builds distributed quantum computing infrastructure.
ZOE
ZOE offers personalised nutrition programmes using advanced at-home testing and mobile applications.
Matthew Newcombe-Ellis
Operating Partner
Sir Winter
Science Partner
The Cambridge startup secured backing from National Grid Partners and Gresham House Ventures to scale its distributed quantum computing architecture.
"When we launched seven years ago, very few were thinking about networked or distributed quantum computing as a strategy for scaling, but we saw it as one of the most urgent and challenging outstanding problems in the industry, and set out to solve it. We’ve made great strides in shaping the market and the technology since then."
The Series A round was led by Ahren, OMX Ventures, and Paladin Capital Group to develop biomanufacturing platforms.
"Synthetic genomics is redefining how we harness biology. Our suite of proprietary technologies and incomparable team allows us to build novel materials and products that will revolutionise drug manufacturing and discovery,"
The investment round was led by New York-based Coefficient Capital with participation from multiple venture firms.
"The way ZOE combines their own science and data to drive huge shifts in consumer behavior towards health immediately impressed us"
The pre-series A round was led by Amadeus Capital Partners, Expeditions Fund, and IQ Capital.
"Large-scale, fault-tolerant quantum computing will bring about the technological revolution of our generation. We have built an exceptional team dedicated to the mission of building the quantum networking infrastructure necessary to make this a reality. We are grateful to the investors who share our vision for their support as we scale and commercialise our solution."
The seed round was led by Ahren to commercialise research from the Medical Research Council.
"I am pleased that we have attracted significant support and seed funding to establish Constructive Bio and capture this opportunity. By taking inspiration from nature and reimagining what life can become we have the opportunity to build the sustainable industries of the future."
